SCHEMBL385886

SCHEMBL385886

CC(C)(C)CC(=O)OC(=O)CC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
MIF P14174 1/20 0.37
LMNA P02545 2/20 0.36
HMGCR P04035 1/20 0.35
CHRM1 P11229 1/20 0.35
TBXA2R P21731 1/20 0.35
ADRA1A P35348 1/20 0.35
TSHR P16473 3/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
HIF1A Q16665 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TK1 P04183 1/20 0.30
TDP1 Q9NUW8 2/20 0.30
FFAR3 O14843 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182236 0.92 ALDH1A1 (0.42) ALDH1A1MIFLMNAHMGCRCHRM1
SCHEMBL28280622 0.87 TRPA1 (0.41) ALDH1A1MIFLMNACYP2C19
SCHEMBL4644220 0.87 ALDH1A1 (0.33) ALDH1A1MIFLMNA
SCHEMBL28224137 0.87 ALDH1A1 (0.33) ALDH1A1MIFLMNA
SCHEMBL2182293 0.86 ALDH1A1 (0.45) ALDH1A1MIFLMNAHMGCRCHRM1
SCHEMBL27475793 0.86 HMGCR (0.36) ALDH1A1MIFLMNAHMGCRCHRM1
SCHEMBL28304864 0.85 ALDH1A1 (0.32) ALDH1A1MIFLMNA
SCHEMBL385887 0.85 ALDH1A1 (0.68) ALDH1A1MIFLMNATSHRFFAR3
SCHEMBL27513878 0.85 MGAM (0.48) ALDH1A1MIFLMNASMN1; SMN2TDP1
SCHEMBL4644724 0.84 CYP2D6 (0.33) MIFLMNATSHRCYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025083736-A1 NOVEL PROCESS FOR THE PREPARATION OF PIRTOBRUTINIB AND ITS INTERMEDIATES THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2025-04-24 WO claimed
WO-2015087351-A2 PROCESS FOR THE PREPARATION OF (1S,3S,7S,10R,11S,12S,16R)-7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-[(1E)-1-METHYL-2-(2-METHYL-4-THIAZOLYL)ETHENYL]-17-OXA-4-AZABICYCLO[14.1.0]HEPTADECANE-5,9-DIONE AND INTERMEDIATES THEREOF MSN LABORATORIES PRIVATE LIMITED (IN) 2015-06-18 WO claimed
CN-1223583-C Peroxyester preparation method ATOFINA (FR) 2005-10-19 CN claimed
CN-1491210-A Process for preparing peroxyesters ���з��ɹ�˾ 2004-04-21 CN claimed
US-12620622-B2 Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same DAIKIN INDUSTRIES, LTD. (JP) 2026-05-05 US disclosed
US-20250260063-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2025-08-14 US disclosed
EP-3780232-B1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE DAIKIN IND LTD (JP) 2025-07-30 EP disclosed
US-20250174720-A1 ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2025-05-29 US disclosed
US-12315885-B2 Electrolytic solution, electrochemical device, lithium-ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2025-05-27 US disclosed
EP-4553918-A1 NEGATIVE ELECTRODE, BATTERY, AND METHOD FOR COVERING BATTERY MATERIAL DAIKIN INDUSTRIES, LTD. (JP) 2025-05-14 EP disclosed
EP-4553940-A1 SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2025-05-14 EP disclosed
EP-4546456-A1 SURFACE TREATMENT AGENT FOR ELECTRODE MATERIAL, POSITIVE ELECTRODE ACTIVE MATERIAL, CURRENT COLLECTOR FOIL, NEGATIVE ELECTRODE ACTIVE MATERIAL, CONDUCTIVE AID, ELECTRODE, BATTERY, METHOD FOR MANUFACTURING POSITIVE ELECTRODE ACTIVE MATERIAL, METHOD FOR MANUFACTURING CURRENT COLLECTOR FOIL, METHOD FOR MANUFACTURING NEGATIVE ELECTRODE ACTIVE MATERIAL, METHOD FOR MANUFACTURING CONDUCTIVE AID, AND METHOD FOR MANUFACTURING ELECTRODE DAIKIN INDUSTRIES, LTD. (JP) 2025-04-30 EP disclosed
US-20060188667-A1 Optical cellulose acylate film and a method of manufacturing the same FUJI PHOTO FILM CO., LTD. (JP) 2006-08-24 US disclosed
US-20060066011-A1 Cellulose acylate film and process for producing the same, and optical film and image display device using the cellulose acylate film FUJI PHOTO FILM CO., LTD. 2006-03-30 US disclosed
US-20060004192-A1 Method of preparing a cellulose acylate, cellulose acylate film, polarizing plate, and liquid crystal display device FUJI PHOTO FILM CO., LTD. 2006-01-05 US disclosed
US-20050239769-A1 Therapeutic compounds for treating dyslipidemic conditions MERCK SHARP & DOHME CORP. 2005-10-27 US disclosed
CN-1223583-C Peroxyester preparation method ATOFINA (FR) 2005-10-19 CN disclosed
EP-1534696-A1 THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS Merck & Co., Inc. (US) 2005-06-01 EP disclosed
CN-1491210-A Process for preparing peroxyesters ���з��ɹ�˾ 2004-04-21 CN disclosed
WO-2004011448-A1 THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS MERCK & CO., INC. (US) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250174720-A1 ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE HCN2, HCN1, HCN3 ALDH1A1 955/4885MIF 4192/4885LMNA 991/4885
US-12620622-B2 Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same ASH2L, OLA1, ODC1 ALDH1A1 1584/4885MIF 3513/4885LMNA 3780/4885
US-20050239769-A1 Therapeutic compounds for treating dyslipidemic conditions NR1H2, NR1H3, LDLR ALDH1A1 1584/4885MIF 2779/4885LMNA 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.